Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve

Abstract excerpt

Neuropathic pain, a heterogeneous condition, affects 7%–10% of the general population. To date, efficacious and safe therapeutic approaches remain limited. Antisense oligonucleotide (ASO) therapy has opened the door to treat spinal muscular atrophy, with many ongoing clinical studies determining its therapeutic utility. ASO therapy for neuropathic pain and peripheral nerve disease requires efficient gene delivery...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Nerve injury and regeneration
• Share to Neurogenetic and Muscular Disorders Research
• Share to Signaling Pathways in Disease